SCHEDULE: Oculis Holding AG: BVCF IV Group Amends Stake Below 5%

BVCF IV, BEYEOTECH, BVCF IV GP, Ltd., and Zhi Yang collectively reported a 4.14% beneficial ownership in Oculis Holding AG as of February 13, 2026, via an amended Schedule 13G filing.

Summary

• The filing is an Amendment No. 2 to a Schedule 13G for Oculis Holding AG.
• The reporting persons are BVCF IV, L.P., BEYEOTECH, BVCF IV GP, Ltd., and Zhi Yang, who have a joint filing agreement dated April 28, 2023.
• The group beneficially owns 2,436,902 Ordinary Shares of Oculis Holding AG.
• This represents 4.14% of the class, based on 58,932,987 Ordinary Shares issued and outstanding as of February 13, 2026.
• BEYEOTECH directly holds the shares and is a wholly-owned subsidiary of BVCF IV, L.P.
• BVCF IV GP, Ltd. is the general partner of BVCF IV, L.P. and may be deemed to have voting control and investment discretion.
• Zhi Yang is the sole shareholder and director of BVCF IV GP, Ltd. and may be deemed to have voting control and investment discretion.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative development, as the reporting group's stake has fallen below the 5% threshold, suggesting a reduction in their investment.

Negatives

• The reporting persons' beneficial ownership in Oculis Holding AG decreased to 4.14%, falling below the 5% threshold that typically triggers an initial Schedule 13G filing, indicating a reduction in their investment.
• A reduction in stake by a significant institutional investor group could be perceived as a decrease in confidence or a strategic reallocation of capital away from Oculis Holding AG.

Future Outlook

NA

Industry Context

StockSavvy.ai notes that Schedule 13G filings provide transparency into significant ownership stakes, which can influence market perception, especially for biotech companies like Oculis Holding AG where investor confidence is crucial. A reduction in a significant stake by an institutional investor group like BVCF IV, bringing it below the 5% threshold, could be interpreted by the market as a shift in investment strategy or outlook.

Stakeholder Impact

• Shareholders: May interpret the reduction in beneficial ownership as a negative signal, potentially impacting share price due to perceived decreased investor confidence.

Key Dates

Recommendation

The filing indicates a reduction in the beneficial ownership of a significant investor group to 4.14%, falling below the 5% threshold. This suggests a decrease in conviction or a reallocation of capital by the reporting persons. While not a strong sell signal without further fundamental analysis of Oculis Holding AG, it removes a potential positive catalyst of increasing institutional ownership and warrants a 'hold' recommendation to observe future developments and company performance.

Keywords

Oculis Holding AG, Schedule 13G, beneficial ownership, BVCF IV, BEYEOTECH, Zhi Yang, Ordinary Shares, equity stake, investment